Genetic diversity of influenza A viruses circulating in Bulgaria during the 2018–2019 winter season Open Access

Abstract

Influenza viruses evolve rapidly and change their antigenic characteristics, necessitating biannual updates of flu vaccines.

The aim of this study was to characterize influenza viruses circulating in Bulgaria during the 2018/2019 season and to identify amino acid substitutions in them that might impact vaccine effectiveness.

Typing/subtyping of influenza viruses were performed using real-time Reverse Transcription-PCR (RT-PCR) and results of phylogenetic and amino acid sequence analyses of influenza strains are presented.

A(H1N1)pdm09 (66 %) predominated over A(H3N2) (34 %) viruses, with undetected circulation of B viruses in the 2018/2019 season. All A(H1N1)pdm09 viruses studied fell into the recently designated 6B.1A subclade with over 50 % falling in four subgroups: 6B.1A2, 6B.1A5, 6B.1A6 and 6B.1A7. Analysed A(H3N2) viruses belonged to subclades 3C.2a1b and 3C.2a2. Amino acid sequence analysis of 36 A(H1N1)pdm09 isolates revealed the presence of six–ten substitutions in haemagglutinin (HA), compared to the A/Michigan/45/2015 vaccine virus, three of which occurred in antigenic sites Sa and Cb, together with four–nine changes at positions in neuraminidase (NA), and a number of substitutions in internal proteins. HA1 D222N substitution, associated with increased virulence, was identified in two A(H1N1)pdm09 viruses. Despite the presence of several amino acid substitutions, A(H1N1)pdm09 viruses remained antigenically similar to the vaccine virus. The 28 A(H3N2) viruses characterized carried substitutions in HA, including some in antigenic sites A, B, C and E, in NA and internal protein sequences.

The results of this study showed the genetic diversity of circulating influenza viruses and the need for continuous antigenic and molecular surveillance.

Funding
This study was supported by the:
  • National Science Fund, Bulgaria (Award Project DH 13-15/2017)
    • Principle Award Recipient: Neli Korsun
  • Welcome Trust (Award FC001030)
    • Principle Award Recipient: John McCauley
  • the UK Medical Research Council (Award FC001030)
    • Principle Award Recipient: John McCauley
  • Cancer Research UK (Award FC001030)
    • Principle Award Recipient: John McCauley
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001198
2020-05-27
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jmm/69/7/986.html?itemId=/content/journal/jmm/10.1099/jmm.0.001198&mimeType=html&fmt=ahah

References

  1. WHO 2018a; Influenza fact sheet. influenza (seasonal) fact sheet. 6 November 2018; available at. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
  2. Gerhard W, Yewdell J, Frankel ME, Webster R. Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature 1981; 290:713–717 [View Article][PubMed]
    [Google Scholar]
  3. Wiley DC, Skehel JJ. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem 1987; 56:365–394 [View Article][PubMed]
    [Google Scholar]
  4. Wilson IA, Cox NJ. Structural basis of immune recognition of influenza virus hemagglutinin. Annu Rev Immunol 1990; 8:737–787 [View Article][PubMed]
    [Google Scholar]
  5. Koel BF, Burke DF, Bestebroer TM, van der Vliet S, Zondag GCM et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 2013; 342:976–979 [View Article][PubMed]
    [Google Scholar]
  6. Koel BF, Mögling R, Chutinimitkul S, Fraaij PL, Burke DF et al. Identification of amino acid substitutions supporting antigenic change of influenza A(H1N1)pdm09 viruses. J Virol 2015; 89:3763–3775 [View Article][PubMed]
    [Google Scholar]
  7. Bedford T, Suchard MA, Lemey P, Dudas G, Gregory V et al. Integrating influenza antigenic dynamics with molecular evolution. Elife 2014; 3:e01914 [View Article][PubMed]
    [Google Scholar]
  8. Harvey WT, Benton DJ, Gregory V, Hall JPJ, Daniels RS et al. Identification of Low- and High-Impact Hemagglutinin Amino Acid Substitutions That Drive Antigenic Drift of Influenza A(H1N1) Viruses. PLoS Pathog 2016; 12:e1005526 [View Article][PubMed]
    [Google Scholar]
  9. Skehel JJ, Stevens DJ, Daniels RS, Douglas AR, Knossow M et al. A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Natl Acad Sci U S A 1984; 81:1779–1783 [View Article][PubMed]
    [Google Scholar]
  10. Zost SJ, Parkhouse K, Gumina ME, Kim K, Diaz Perez S et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci U S A 2017; 114:12578–12583 [View Article][PubMed]
    [Google Scholar]
  11. Matrosovich M, Matrosovich T, Carr J, Roberts NA, Klenk H-D. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol 2003; 77:8418–8425 [View Article][PubMed]
    [Google Scholar]
  12. WHO 2011b; Manual for the laboratory diagnosis and virological surveillance of influenza. http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf
  13. GISAID Available at. https://www.gisaid.org/
  14. Adobe Illustrator CC 2015; 3. Available at https://helpx.adobe.com/uk/illustrator/using/whats-new.html
    [Google Scholar]
  15. MEGA Molecular Evolutionary Genetics Analysis (MEGA, version 6.06) software. Available at. http://www.megasoftware.net/
  16. FluSurver Available at:. http://flusurver.bii.a-star.edu.sg
  17. Hussain S, Miller JL, Harvey DJ, Gu Y, Rosenthal PB et al. Strain-Specific antiviral activity of iminosugars against human influenza A viruses. J Antimicrob Chemother 2015; 70:136–152 [View Article][PubMed]
    [Google Scholar]
  18. Beer K, Dai M, Howell S, Rijal P, Townsend AR et al. Characterization of neutralizing epitopes in antigenic site B of recently circulating influenza A(H3N2) viruses. J Gen Virol 2018; 99:1001–1011 [View Article][PubMed]
    [Google Scholar]
  19. WHO 2019c; Worldwide Influenza Centre, London. September 2019 Interim Report. Report prepared for the WHO annual consultation on the composition of influenza vaccine for the Southern Hemisphere 2020. 23rd – 26th September 2019. Available at. https://www.crick.ac.uk/sites/default/files/201910/CrickSH2019VCMreport_v2.pdf
  20. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 1982; 31:417–427 [View Article][PubMed]
    [Google Scholar]
  21. Graham M, Liang B, Van Domselaar G, Bastien N, Beaudoin C et al. Nationwide molecular surveillance of pandemic H1N1 influenza A virus genomes: Canada, 2009. PLoS One 2011; 6:e16087 [View Article][PubMed]
    [Google Scholar]
  22. Maurer-Stroh S, Ma J, Lee RTC, Sirota FL, Eisenhaber F. Mapping the sequence mutations of the 2009 H1N1 influenza A virus neuraminidase relative to drug and antibody binding sites. Biol Direct 2009; 4:18 [View Article][PubMed]
    [Google Scholar]
  23. Colman PM, Hoyne PA, Lawrence MC. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol 1993; 67:2972–2980 [View Article][PubMed]
    [Google Scholar]
  24. Belshe RB, Smith MH, Hall CB, Betts R, Hay AJ. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol 1988; 62:1508–1512 [View Article][PubMed]
    [Google Scholar]
  25. Fang Q, Gao Y, Chen M, Guo X, Yang X et al. Molecular epidemiology and evolution of A(H1N1)pdm09 and H3N2 virus during winter 2012-2013 in Beijing, China. Infect Genet Evol 2014; 26:228–240 [View Article][PubMed]
    [Google Scholar]
  26. WHO 2016d; Summary of neuraminidase amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (Last updated 26 April 2018).. http://www.who.int/influenza/gisrs_laboratory/antiviral_susceptibility/nai_overview/en/
  27. Takashita E, Daniels RS, Fujisaki S, Gregory V, Gubareva LV et al. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018. Antiviral Res 2020; 175:104718 [View Article][PubMed]
    [Google Scholar]
  28. Korsun NS, Angelova SG, Trifonova IT, Georgieva IL, Tzotcheva IS et al. Predominance of influenza B/Yamagata lineage viruses in Bulgaria during the 2017/2018 season. Epidemiol Infect 2019; 147:e76 [View Article][PubMed]
    [Google Scholar]
  29. Segaloff H, Melidou A, Adlhoch C, Pereyaslov D, Robesyn E et al. Co-circulation of influenza A(H1N1)pdm09 and influenza A(H3N2) viruses, World Health Organization (WHO) European Region, October 2018 to February 2019. Euro Surveill 2019; 24: [View Article][PubMed]
    [Google Scholar]
  30. Korsun N, Angelova S, Teodosieva A. Virological surveillance of influenza in four recent Post-Pandemic seasons (2010/11 to 2013/14) in Bulgaria. Cent Eur J Public Health 2016; 24:180–187 [View Article][PubMed]
    [Google Scholar]
  31. Korsun N, Angelova S, Gregory V, Daniels R, Georgieva I et al. Antigenic and genetic characterization of influenza viruses circulating in Bulgaria during the 2015/2016 season. Infect Genet Evol 2017; 49:241–250 [View Article][PubMed]
    [Google Scholar]
  32. Ilyicheva T, Durymanov A, Susloparov I, Kolosova N, Goncharova N et al. Fatal cases of seasonal influenza in Russia in 2015-2016. PLoS One 2016; 11:e0165332 [View Article][PubMed]
    [Google Scholar]
  33. Horwood PF, Karlsson EA, Horm SV, Ly S, Heng S et al. Circulation and characterization of seasonal influenza viruses in Cambodia, 2012-2015. Influenza Other Respir Viruses 2019; 13:465–476 [View Article][PubMed]
    [Google Scholar]
  34. Strengell M, Ikonen N, Ziegler T, Julkunen I. Minor changes in the hemagglutinin of influenza A(H1N1)2009 virus alter its antigenic properties. PLoS One 2011; 6:e25848 [View Article][PubMed]
    [Google Scholar]
  35. Gao J, Couzens L, Burke DF, Wan H, Wilson P et al. Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies. mBio 2019; 10:e00307–00319 [View Article][PubMed]
    [Google Scholar]
  36. WHO 2019e; Recommended composition of influenza virus vaccines for use in the 2019-2020 northern hemisphere influenza season; Available at:. https://www.who.int/influenza/vaccines/virus/recommendations/2019_20_north/en/
  37. Glinsky GV. Genomic analysis of pandemic (H1N1) 2009 reveals association of increasing disease severity with emergence of novel hemagglutinin mutations. Cell Cycle 2010; 9:958–970 [View Article][PubMed]
    [Google Scholar]
  38. Kolosova NP, Ilyicheva TN, Danilenko AV, Bulanovich JA, Svyatchenko SV et al. Severe cases of seasonal influenza in Russia in 2017-2018. PLoS One 2019; 14:e0220401 [View Article][PubMed]
    [Google Scholar]
  39. Andrés C, Peremiquel-Trillas P, Gimferrer L, Piñana M, Codina MG et al. Molecular influenza surveillance at a tertiary university hospital during four consecutive seasons (2012-2016) in Catalonia, Spain. Vaccine 2019; 37:2470–2476 [View Article][PubMed]
    [Google Scholar]
  40. Chutinimitkul S, Herfst S, Steel J, Lowen AC, Ye J et al. Virulence-associated substitution D222G in the hemagglutinin of 2009 pandemic influenza A(H1N1) virus affects receptor binding. J Virol 2010; 84:11802–11813 [View Article][PubMed]
    [Google Scholar]
  41. Liu Y, Childs RA, Matrosovich T, Wharton S, Palma AS et al. Altered receptor specificity and cell tropism of D222G hemagglutinin mutants isolated from fatal cases of pandemic A(H1N1) 2009 influenza virus. J Virol 2010; 84:12069–12074 [View Article][PubMed]
    [Google Scholar]
  42. Rambaut A, Pybus OG, Nelson MI, Viboud C, Taubenberger JK et al. The genomic and epidemiological dynamics of human influenza A virus. Nature 2008; 453:615–619 [View Article][PubMed]
    [Google Scholar]
  43. Kawakami C, Yamayoshi S, Akimoto M, Nakamura K, Miura H et al. Genetic and antigenic characterisation of influenza A(H3N2) viruses isolated in Yokohama during the 2016/17 and 2017/18 influenza seasons. Euro Surveill 2019; 24:pii=1800467 [View Article][PubMed]
    [Google Scholar]
  44. Schulze IT. Effects of glycosylation on the properties and functions of influenza virus hemagglutinin. J Infect Dis 1997; 176 Suppl 1:S24–S28 [View Article][PubMed]
    [Google Scholar]
  45. Simon B, Pichon M, Valette M, Burfin G, Richard M et al. Whole Genome Sequencing of A(H3N2) Influenza Viruses Reveals Variants Associated with Severity during the 2016–2017 Season. Viruses 2019; 11:108–115 [View Article]
    [Google Scholar]
  46. Wedde M, Biere B, Wolff T, Schweiger B. Evolution of the hemagglutinin expressed by human influenza A(H1N1)pdm09 and A(H3N2) viruses circulating between 2008-2009 and 2013-2014 in Germany. Int J Med Microbiol 2015; 305:762–775 [View Article][PubMed]
    [Google Scholar]
  47. Al Khatib HA, Al Thani AA, Gallouzi I, Yassine HM. Epidemiological and genetic characterization of pH1N1 and H3N2 influenza viruses circulated in MENA region during 2009-2017. BMC Infect Dis 2019; 19:314 [View Article][PubMed]
    [Google Scholar]
  48. Hammond A, Hunda K, Laurenson-Schafer H, Cozza V, Maharjan B et al. Review of the 2018–2019 influenza season in the Northern hemisphere. Wkly Epidemiol Rec 2019; 32:345–364
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001198
Loading
/content/journal/jmm/10.1099/jmm.0.001198
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed